Additional file 1 of Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years

Autor: Gholami, Fatemeh, Hamidi Farahani, Ramin, Karimi Rahjerdi, Ahmad, Ahi, Mohammadreza, Sheidaei, Ali, Gohari, Kimiya, Rahimi, Zahra, Ansarifar, Akram, Basiri, Pouria, Moradi, Milad, Jahangiri, Arash, Naderi, Kosar, Ghasemi, Soheil, Khatami, Pezhman, Honari, Mohsen, Khodaverdloo, Samane, Shooshtari, Mohammad, Mehr Azin, Hajar, Moradi, Sohrab, Shafaghi, Batool, Allahyari, Hossein, Monazah, Arina, Khodaei Poor, Ali, Taghva, Zahra, Bakhshande, Hooman, Karimi Nia, Mohammad, Solaymani Dodaran, Masoud, Forooghizade, Mohsen
Rok vydání: 2023
DOI: 10.6084/m9.figshare.22614317
Popis: Additional file 1. Inclusion and Exclusion (Eligibility) criteria (pages:2-5). Safety Reporting Guidelines (pages:6-9). Diagram of participants' scheduled visits (page 11). COVID-19 case definitions (pages:12-13). Scoring the severity of local adverse reactions, eTable 5 and Scoring the severity of systemic adverse reactions, eTable 6 (pages:14-15). Scoring the severity of the adverse reactions, eTable 7 and eTable 8 (pages:16-18).
Databáze: OpenAIRE